classical Hodgkin's lymphoma
Haematology · 2017–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin First-line treatment of advanced (Stage III or IV) classical CD30+ Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (A+AVD). | Mar 2024 | Not recommended | input received Leukaemia Foundation |
| pembrolizumab Treatment of relapsed or refractory classical Hodgkin's Lymphoma (rrcHL) in patients who have undergone autologous stem cell transplant or are not suitable for… | Aug 2017 | Recommended with restriction | no section in document |
| pembrolizumab Treatment of relapsed or refractory classical Hodgkin's lymphoma (rrcHL) in patients who have progressed following autologous stem cell transplant (ASCT), or… | Jul 2017 | Deferred | 125 individuals |
Who spoke
Leukaemia Foundation
What the PBS pays
$761M in government benefit over 2024–25, across 88,651 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| brentuximab vedotin | $21.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| pembrolizumabPembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | recommended restricted | 2024-05 |
| pembrolizumabPembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | not recommended | 2022-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.